Tarlatamab combination lifts median survival to 21.1 months in lung cancer trial
In the phase 3 DeLLphi-305 trial, adding tarlatamab to durvalumab after initial chemoimmunotherapy extended median overall survival to 21.1 months, compared with 12.7 months on durvalumab alone. The results, published in the New England Journal of Medicine and presented at the ESMO Congress, also showed longer progression-free survival; the trial involved 563 people with extensive-stage small-cell lung cancer whose disease had not progressed after initial treatment.
Bottom line — The combination cut the risk of death by 58% in DeLLphi-305, though longer follow-up and access remain concerns.
Go deeper 6
-
PubMed’s trial summary reports median progression-free survival of 7.4 months with the combination, versus 1.9 months with durvalumab alone.
-
The combination group’s objective response rate was 26.4%, compared with 4.1% in the durvalumab group, according to Oncology News Central.
-
PubMed reports grade 3 or higher adverse events in 46.8% of patients on the combination and 40.6% on durvalumab alone.
-
Medthority reports cytokine release syndrome in 49.6% of the combination group; severe cases were uncommon, at 0.4%.
-
Oncology News Central says invited discussant Stephen Liu flagged unanswered questions about brain metastases, quality of life and longer-term survival.
-
Liu also said access to tarlatamab remains a barrier, according to Oncology News Central.